Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer

被引:0
|
作者
Zimmer, Philipp [1 ]
Esser, Tobias [1 ]
Lueftner, Diana [3 ,4 ]
Schuetz, Florian [5 ]
Baumann, Freerk T. [6 ]
Rody, Achim [7 ]
Schneeweiss, Andreas [8 ,9 ]
Hartkopf, Andreas D. [10 ]
Decker, Thomas [11 ]
Uleer, Christoph [12 ]
Stoetzer, Oliver J. [13 ]
Foerster, Frank [14 ]
Schmidt, Marcus [15 ]
Mundhenke, Christoph [16 ]
Steindorf, Karen [17 ]
Tesch, Hans [18 ]
Jackisch, Christian [19 ]
Fischer, Thomas [20 ]
Hanson, Sven [21 ]
Kreuzeder, Julia [21 ]
Guderian, Gernot [21 ]
Fasching, Peter A. [22 ]
Bloch, Wilhelm [2 ]
机构
[1] TU Dortmund Univ, Inst Sport & Sport Sci, Div Performance & Hlth Sports Med, Dortmund, Germany
[2] German Sport Univ Cologne, Dept Mol & Cellular Sports Med, Cologne, Germany
[3] Immanuel Hosp Mark Schweiz, Buckowrudersdorf, Germany
[4] Med Univ Brandenburg Theodor Fontane, Buckowrudersdorf, Germany
[5] Univ Hosp Heidelberg, Dept Obstet & Gynecol, Heidelberg, Germany
[6] Univ Hosp Cologne, Ctr Integrated Oncol, Dept Internal Med 1, Cologne, Germany
[7] Univ Hosp Schleswig Holstein, Dept Obstet & Gynecol, Lubeck, Germany
[8] Heidelberg Univ Hosp, Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[9] German Canc Res Ctr, Heidelberg, Germany
[10] Univ Hosp Tuebingen, Dept Womens Hlth, Tubingen, Germany
[11] Med Ctr Hematol & Oncol Ravensburg, Ravensburg, Germany
[12] Gynecol Grp Practice, Hildesheim, Germany
[13] Med Ctr Hematol & Oncol Munich, Munich, Germany
[14] Poliklin GmbH Chemnitz, Chemnitz, Germany
[15] Univ Med Ctr Mainz, Dept Obstet & Gynecol, Dept Conservat & Mol Gynecol Oncol, Mainz, Germany
[16] Bayreuth Hosp, Dept Obstet & Gynecol, Bayreuth, Germany
[17] German Canc Res Ctr, Div Phys Act Prevent & Canc, Heidelberg, Germany
[18] Ctr Hematol & Oncol Bethanien, Frankfurt, Germany
[19] Sana Klinikum Offenbach, Dept Obstet & Gynecol, Offenbach, Germany
[20] Winicker Norimed GmbH Med Res, Nurnberg, Germany
[21] Novartis Pharm GmbH, Nurnberg, Germany
[22] Univ Hosp Erlangen, Dept Gynecol & Obstet, Erlangen, Germany
来源
BMC MEDICINE | 2024年 / 22卷 / 01期
关键词
Physical activity; Exercise; Breast cancer; Adverse events; Survival; Fatigue; Quality of life; QUALITY-OF-LIFE; EXERCISE; MORTALITY; ASSOCIATION; FATIGUE; METAANALYSIS; RECURRENCE; VALIDITY;
D O I
10.1186/s12916-024-03671-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Increased levels of physical activity are associated with a reduction of breast cancer mortality, especially in postmenopausal women with positive hormone receptor status. So far, previous observational case-control and cohort studies have focused on associations between overall leisure time physical activity and survival of women with breast cancer in general. Methods In this multicenter prospective cohort study, conducted in Germany between 30th August 2012 to 29th December 2017, we investigated general physical activity in a homogenous sample of n = 1440 postmenopausal women with advanced (inoperable locally advanced or metastatic), hormone receptor-positive breast cancer receiving the same therapy (everolimus and exemestane). Self-reported physical activity was assessed using the Godin Leisure Time Exercise Questionnaire (GLTEQ) before and every 3 months during treatment. Participants were then classified into "active" and "insufficiently active" to screen their activity behavior the week prior to medical treatment. In addition, changes in physical activity patterns were assessed. Adjusted Cox regression analyses were performed for the activity categories to determine hazard ratios (HR). Besides progression-free survival (PFS), adverse events (AEs), QoL, and fatigue were assessed every 3 months until study termination. Results Compared to "insufficiently active" patients, "active" individuals indicated a significantly longer PFS (HR: 0.84 [0.74; 0.984], p = .0295). No significant differences were observed for changes of physical activity behavior. Patients who reported to be "active" at baseline revealed significantly fewer AEs compared to "insufficiently" active patients. In detail, both severe and non-severe AEs occurred less frequently in the "active" patients group. In line with that, QoL and fatigue were better in physical "active" patients compared to their insufficient active counterparts at the last post-baseline assessment. Participants who remained or become active indicated less AEs, a higher QoL, and reduced fatigue levels. Conclusions Physical activity behavior prior to medical treatment might have prognostic value in patients with advanced breast cancer in terms of extending the PFS. Moreover, physical activity before and during treatment may reduce treatment-related side effects and improve patients' QoL and fatigue. Trial registration EUPAS9462. Registered 30th October 2012 "retrospectively registered."
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
    Saad, E. D.
    Katz, A.
    Hoff, P. M.
    Buyse, M.
    ANNALS OF ONCOLOGY, 2010, 21 (01) : 7 - 12
  • [22] Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer
    Hamada, Tsuyoshi
    Nakai, Yousuke
    Isayama, Hiroyuki
    Yasunaga, Hideo
    Matsui, Hiroki
    Takahara, Naminatsu
    Mizuno, Suguru
    Kogure, Hirofumi
    Matsubara, Saburo
    Yamamoto, Natsuyo
    Tada, Minoru
    Koike, Kazuhiko
    EUROPEAN JOURNAL OF CANCER, 2016, 65 : 11 - 20
  • [23] Mammography radiomics features at diagnosis and progression-free survival among patients with breast cancer
    Luo, Chuanxu
    Zhao, Shuang
    Peng, Cheng
    Wang, Chengshi
    Hu, Kejia
    Zhong, Xiaorong
    Luo, Ting
    Huang, Juan
    Lu, Donghao
    BRITISH JOURNAL OF CANCER, 2022, 127 (10) : 1886 - 1892
  • [24] Preoperative hysteroscopy shortened progression-free survival in advanced FIGO stage in endometrial cancer: Ten year analysis
    Miao, Huixian
    Zhang, Lin
    Jiang, Yi
    Wan, Yicong
    Yuan, Lin
    Cheng, Wenjun
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2024, 164 (03) : 1195 - 1204
  • [25] Cholangitis and Interruptions of Neoadjuvant Chemotherapy Associate with Reduced Overall and Progression-Free Survival in Pancreatic Cancer
    Vehvilaeinen, Sini
    Kuuliala, Antti
    Udd, Marianne
    Nurmi, Anna
    Peltola, Katriina
    Haglund, Caj
    Kylaenpaeae, Leena
    Seppaenen, Hanna
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (04) : 2621 - 2631
  • [26] Cholangitis and Interruptions of Neoadjuvant Chemotherapy Associate with Reduced Overall and Progression-Free Survival in Pancreatic Cancer
    Sini Vehviläinen
    Antti Kuuliala
    Marianne Udd
    Anna Nurmi
    Katriina Peltola
    Caj Haglund
    Leena Kylänpää
    Hanna Seppänen
    Annals of Surgical Oncology, 2024, 31 : 2621 - 2631
  • [27] Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm
    Chi, Dennis S.
    Eisenhauer, Eric L.
    Zivanovic, Oliver
    Sonoda, Yukio
    Abu-Rustum, Nadeem R.
    Levine, Douglas A.
    Guile, Matthew W.
    Bristow, Robert E.
    Aghajanian, Carol
    Barakat, Richard R.
    GYNECOLOGIC ONCOLOGY, 2009, 114 (01) : 26 - 31
  • [28] Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients
    Huang, Lihong
    Wei, Yongyue
    Shen, Sipeng
    Shi, Qianwen
    Bai, Jianling
    Li, Jin
    Qin, Shukui
    Yu, Hao
    Chen, Feng
    ONCOTARGET, 2017, 8 (17) : 29346 - 29354
  • [29] Modification of the association between recreational physical activity and survival after breast cancer by promoter methylation in breast cancer-related genes
    McCullough, Lauren E.
    Chen, Jia
    Cho, Yoon Hee
    Khankari, Nikhil K.
    Bradshaw, Patrick T.
    White, Alexandra J.
    Teitelbaum, Susan L.
    Terry, Mary Beth
    Neugut, Alfred I.
    Hibshoosh, Hanina
    Santella, Regina M.
    Gammon, Marilie D.
    BREAST CANCER RESEARCH, 2017, 19
  • [30] Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
    Bilici, Ahmet
    Ustaalioglu, Bala Basak Oven
    Ercan, Serif
    Orcun, Asuman
    Seker, Mesut
    Salepci, Taflan
    Gumus, Mahmut
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (02) : 309 - 316